[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-366830-105":59,"doc-detail-366830-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","cost-effectiveness-analysis-of-hpv-vaccination-of-men-who-have-sex-with-men-in-germany","Cost-effectiveness analysis of HPV vaccination of men who have sex with men in Germany","","Men who have sex with men (MSM) face a high risk of human papillomavirus (HPV) infection and HPV-related diseases. In Germany, gender-neutral HPV vaccination is recommended for adolescents, but adult MSM are not included, limiting potential public health and health-economic benefits. This study quantifies the impact of extending 9-valent HPV vaccination to MSM aged 18–26 or 18–45 versus vaccinating adolescent boys only, using a dynamic transmission model with an integrated HIV component. Results include prevented cancers, deaths, anogenital warts, and favorable cost-effectiveness outcomes.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/cost-effectiveness-analysis-of-hpv-vaccination-of-men-who-have-sex-with-men-in-germany/366830/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/cost-effectiveness-analysis-of-hpv-vaccination-of-men-who-have-sex-with-men-in-germany/366830.png","ImageObject",300,407,{"name":92,"@type":93},"PakDamar76","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-19","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why is HPV vaccination expansion for adult MSM considered in Germany?","Question",{"text":113,"@type":114},"MSM have higher HPV infection rates and resulting HPV-related disease burden, but adult MSM are not currently included in Germany’s vaccination recommendation, so they do not benefit from adolescent vaccination advantages.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What model was used to evaluate the vaccination scenarios?",{"text":118,"@type":114},"A dynamic HPV transmission model was developed with an integrated HIV model and economic outcomes, assessing impacts of 9-valent HPV vaccination on infections and HPV-related cancers and anogenital warts.",{"name":120,"@type":111,"acceptedAnswer":121},"What health outcomes and cost-effectiveness results were reported?",{"text":122,"@type":114},"Vaccinating MSM aged 18–26 and 18–45 could prevent additional cancers, deaths, and anogenital warts, with incremental cost-effectiveness ratios (ICERs) reported as 35,300.09€/QALY and 42,088.06€/QALY respectively versus vaccinating adolescent boys only.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},366830,1790418804,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":41,"preview_page_count":19,"preview_urls":146},962090893057,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Infection (2025) 53:2371–2382  \n[https://doi.org/10.1007/s15010-025-02567-z](https://doi.org/10.1007/s15010-025-02567-z)  \nRESEARCH  \nCost-effectiveness analysis of HPV vaccination of men who have sex with men in Germany  \nCody Palmer1,8 · Cornelia Wähner2 · RegineWölle3 · Alexander Kreuter4 · Jens Peter Klussmann5 · Julian Witte6 · Agnes Luzak3 · Miriam Reuschenbach7  \nReceived: 2 July 2024 / Accepted: 16 May 2025 / Published online: 13 June 2025  \n© Merck & Co., Inc., Rahway, NJ, USA and its affiliates, and Alexander Kreuter, Jens Peter Klussmann, Julian Witte 2025  \nAbstract  \nIntroduction Men who have sex with men (MSM) have a high risk of human papillomavirus (HPV) infection and HPVrelated diseases. While gender neutral HPV vaccination between the ages of 9–14 years (with the option for catch-up between 15-and 17-years-of-age) has been recommended in Germany since 2018, adult MSM are currently not included and thus do not benefit from its advantages. This analysis aims to quantify the reduction in public health and health economic burden of including 18–26-year-old or 18–45-year-old MSM in the national HPV vaccination recommendation, compared to the status quo of vaccinating adolescent boys only.  \nMethods We developed a dynamic transmission model of HPV, with an integrated HIV model, to analyze the potential impact of the 9-valent HPV vaccination on HPV infections and HPV-related diseases (anal, penile, and oropharyngeal cancers, and anogenital warts). By including economic outcomes, the model provides estimates of the cost-effectiveness of HPV vaccination among adult MSM in Germany.  \nResults Vaccinating MSM aged 18–26 years could prevent an additional 2,583 anal, penile and oropharyngeal cancers, 709 deaths and 81,372 anogenital warts. Expanding vaccination to MSM aged 18–45 years, 4,091 cancers, 1,516 deaths and 114,117 anogenital warts could be averted. The highest reductions were found in anal cancers and anogenital warts; significant incidence reductions in cancers were seen within about 20 years. Vaccinating 18–26 and 18-45-year-old MSM resulted in Incremental Cost-Effectiveness Ratios (ICERs) of 35,300.09€/QALY and 42,088.06€/QALY, respectively, when compared to the vaccination of adolescent boys only.  \nConclusions Vaccination of MSM up to 26 and 45 years of age can profoundly accelerate beneficial public health outcomes while reducing the economic burden of HPV-related cancers and anogenital warts in a cost-effective way compared to vaccinating adolescent boys only.  \nKeywords Human papillomavirus · Vaccination · Men who have sex with men · Disease burden · Economic burden · Dynamic transmission model  \n􀀍 Cody Palmer [cody.palmer@merck.com](cody.palmer@merck.com)  \n1 Health Economic and Decision Sciences, BARDS, Merck & Co., Inc., Rahway, NJ, USA  \n2 Department of Medical Affairs, MSD Sharp & Dohme GmbH, Levelingstr. 4a, 81673 Munich, Germany  \n3 Department of Market Access, MSD Sharp & Dohme GmbH, Levelingstr. 4a, 81673 Munich, Germany  \n4 Department of Dermatology, Venerology, and Allergology, Helios St Elisabeth Hospital Oberhausen, University Witten/ Herdecke, Oberhausen, Germany  \n5 Department of Otorhinolaryngology, Head and Neck Surgery, Medical Faculty, University of Cologne, Cologne, Germany  \n6 Vandage GmbH, CEO, Detmolder Straße 30,  \n33604 Bielefeld, Germany  \n7 Global Medical and Scientific Affairs, MSD Sharp & Dohme GmbH, Levelingstr. 4a, 81673 Munich, Germany  \n8 770 Sumneytown Pike, West Point, PA 19486, USA  \nIntroduction  \nHuman papillomaviruses (HPV) are the most common form of sexually transmitted pathogens, and nearly 100% of all women and men become infected with HPV at least once in their lifetime [1] . These infections can lead to a broad spectrum of benign, premalignant and malignant mucosal lesions in both men and women, including anogenital warts and various types of cancer [2]. Globally, HPV causes about 85% of anal, 40% of oropharyngeal, and 45% of penile cancers in men [3] . In Ger","cbCaiveb7OG3WDpn","https://ap.wps.com/l/cbCaiveb7OG3WDpn","pdf",1211462,12,"English","# Abstract\n## Introduction\n## Methods\n## Results\n## Conclusions\n# Main Text\n## Epidemiology and burden in MSM","[{\"question\":\"Why is HPV vaccination expansion for adult MSM considered in Germany?\",\"answer\":\"MSM have higher HPV infection rates and resulting HPV-related disease burden, but adult MSM are not currently included in Germany’s vaccination recommendation, so they do not benefit from adolescent vaccination advantages.\"},{\"question\":\"What model was used to evaluate the vaccination scenarios?\",\"answer\":\"A dynamic HPV transmission model was developed with an integrated HIV model and economic outcomes, assessing impacts of 9-valent HPV vaccination on infections and HPV-related cancers and anogenital warts.\"},{\"question\":\"What health outcomes and cost-effectiveness results were reported?\",\"answer\":\"Vaccinating MSM aged 18–26 and 18–45 could prevent additional cancers, deaths, and anogenital warts, with incremental cost-effectiveness ratios (ICERs) reported as 35,300.09€/QALY and 42,088.06€/QALY respectively versus vaccinating adolescent boys only.\"}]","Cost-effectiveness analysis of HPV vaccination of men who have sex with men in Germany | PDF",1790167805,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9e00b376c160a2b7e7e4a37042042ce7.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/068e643ef893d9a71ab974f38924e983.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/af7b30fa206e7cb79f6f8d7719e2244c.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d5f790367682cf6c5528e088abc4cabf.webp",980,1301]